NASDAQ:ANIK Anika Therapeutics Q3 2026 Earnings Date & Estimates $19.23 -0.30 (-1.54%) Closing price 04:00 PM EasternExtended Trading$19.24 +0.00 (+0.03%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Anika Therapeutics is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Anika Therapeutics in Q3 2026Anika Therapeutics is expected to post earnings of $0.42 per share on revenue of $29.44 million. In the same quarter a year earlier Anika Therapeutics reported $0.04 per share on revenue of $27.82 million. Anika Therapeutics last reported on July 29, 2026, posting $0.42 per share and beating the $0.03 consensus estimate. Anika Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.42Expected Revenue$29.44 millionPrior-Year EPS$0.04Prior-Year Revenue$27.82 millionExpected EPS Growth+950.0%Expected Revenue Growth+5.8%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.42 (Beat by +$0.39)Last Quarter Revenue$32.61 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Anika Therapeutics Q3 2026 Earnings FAQ When does Anika Therapeutics report Q3 2026 earnings? Anika Therapeutics (NASDAQ:ANIK) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. What time is Anika Therapeutics' Q3 2026 earnings call? Anika Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Anika Therapeutics? Analysts expect Anika Therapeutics to post earnings of $0.42 per share for Q3 2026. How much revenue is Anika Therapeutics expected to report? The consensus revenue estimate for Anika Therapeutics is $29.44 million for Q3 2026. Anika Therapeutics Earnings HeadlinesAnika (ANIK) Q2 2026 Earnings Call TranscriptAugust 8, 2026 | finance.yahoo.comAnika Therapeutics Lifts Outlook After Margin SurgeAugust 2, 2026 | tipranks.comA dividend every week of the yearMost dividend stocks pay quarterly, leaving long stretches of silence between paydays. For investors covering real expenses, that rhythm rarely lines up with the bills. Nathan Slaughter, Chief Investment Strategist at High-Yield Investing, built a full 52-week calendar by sequencing quality dividend payers so every week is covered, including bonus dividends that cluster from December through February.October 8 at 1:00 AM | Market Savvy (Ad)Anika Therapeutics (ANIK) Stock Fair Value Rises After Q2 Beat And Higher GuidanceAugust 2, 2026 | finance.yahoo.comThese 2 biotech stocks hit new 52-week highs today – and CORT clocked its best day in nearly 16 monthsJuly 30, 2026 | msn.comClarevia Ventures Welcomes Cheryl R. Blanchard, Ph.D., as Executive in ResidenceJuly 30, 2026 | finance.yahoo.comSee More Anika Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Anika Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anika Therapeutics and other key companies, straight to your email. Email Address About Anika TherapeuticsAnika Therapeutics (NASDAQ:ANIK), Inc. is a medical technology company focused on joint preservation and orthopedic care. The company develops and commercializes products designed to relieve pain, restore mobility and support the repair or protection of damaged joints and tissues, with an emphasis on therapies based on hyaluronic acid and other regenerative technologies. Anika’s portfolio includes viscosupplementation products for osteoarthritis, including Orthovisc, Monovisc and Cingal. These injectable treatments are intended to supplement the natural synovial fluid in the knee and other joints. The company also offers products for sports medicine, soft-tissue repair and regenerative care, including Hyaloglide, an adhesion barrier used in tendon-repair procedures, along with other surgical and orthopedic solutions. Founded in 1983 and headquartered in Bedford, Massachusetts, Anika has built its business around the development and commercialization of hyaluronic-acid-based medical products. Its products are marketed in the United States and internationally through a combination of direct commercial activities and distribution partners, serving orthopedic surgeons, sports-medicine specialists and other healthcare providers.View Anika Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
